Despite these limitations, the study provides the largest and most comprehensive risk analysis to date of neurologic irAEs in melanoma patients treated with combination anti-PD-1/CTLA-4 immunotherapy versus anti-PD-1 monotherapy. The gene discussed is CTLA4; the disease is melanoma.